| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-2600(13)70006-7 |
| P698 | PubMed publication ID | 24429093 |
| P50 | author | Ruth Tal-Singer | Q75469591 |
| William MacNee | Q38326286 | ||
| Jørgen Vestbo | Q41838693 | ||
| P2093 | author name string | David A Lomas | |
| Bartolome Celli | |||
| Edwin K Silverman | |||
| Per Bakke | |||
| Stephen I Rennard | |||
| Harvey O Coxson | |||
| Courtney Crim | |||
| Bruce E Miller | |||
| Nestor L Müller | |||
| Alvar Agusti | |||
| Ruth J Mayer | |||
| Peter Ma Calverley | |||
| Asger Dirksen | |||
| Julie C Yates | |||
| Lisa D Edwards | |||
| Annelyse Duvoix | |||
| Emiel Fm Wouters | |||
| Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators | |||
| Paola Nasute Fauerbach | |||
| P2860 | cites work | Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. | Q51837763 |
| Monitoring the progress of emphysema by repeat computed tomography scans with focus on noise reduction. | Q51861049 | ||
| Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. | Q53077968 | ||
| Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. | Q53409072 | ||
| Short-term effect of changes in smoking behaviour on emphysema quantification by CT | Q57605115 | ||
| Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | Q57955820 | ||
| Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) | Q57955885 | ||
| Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort | Q58316998 | ||
| "Density mask". An objective method to quantitate emphysema using computed tomography | Q67928447 | ||
| The natural history of chronic airflow obstruction | Q24674578 | ||
| Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema | Q29416999 | ||
| The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 | ||
| Polymorphisms in the Superoxide Dismutase-3 Gene Are Associated with Emphysema in COPD | Q34074050 | ||
| Characterisation of COPD heterogeneity in the ECLIPSE cohort | Q34149510 | ||
| Surfactant proteins SP-A and SP-D: structure, function and receptors. | Q34457931 | ||
| Epidemiology, radiology, and genetics of nicotine dependence in COPD. | Q34552656 | ||
| Prediction of the rate of decline in FEV(1) in smokers using quantitative Computed Tomography. | Q34560231 | ||
| Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study | Q34774357 | ||
| Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD | Q34780176 | ||
| Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease | Q35042489 | ||
| Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes | Q35249531 | ||
| Small-airway obstruction and emphysema in chronic obstructive pulmonary disease | Q35615301 | ||
| COPD association and repeatability of blood biomarkers in the ECLIPSE cohort | Q35637295 | ||
| Genetic determinants of emphysema distribution in the national emphysema treatment trial | Q36103482 | ||
| Lung structure and function in cigarette smokers | Q36566266 | ||
| A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy | Q40790470 | ||
| Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. | Q46150950 | ||
| Pulmonary emphysema: objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry | Q47653501 | ||
| Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. | Q48100352 | ||
| Factors influencing the decline in lung density in a Danish lung cancer screening cohort. | Q50555920 | ||
| Progression parameters for emphysema: a clinical investigation. | Q51103937 | ||
| Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. | Q51171610 | ||
| Changes in forced expiratory volume in 1 second over time in COPD. | Q51521679 | ||
| Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. | Q51593787 | ||
| P433 | issue | 2 | |
| P921 | main subject | pulmonary emphysema | Q188605 |
| chronic obstructive pulmonary disease | Q199804 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 129-136 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | The Lancet. Respiratory medicine | Q27724908 |
| P1476 | title | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study | |
| P478 | volume | 1 |
| Q47244932 | A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging: The MESA Lung Study |
| Q33913351 | A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease |
| Q41112661 | A mixed phenotype of airway wall thickening and emphysema is associated with dyspnea and hospitalization for chronic obstructive pulmonary disease. |
| Q38308369 | A review on airway biomarkers: exposure, effect and susceptibility. |
| Q42374558 | A size-based emphysema severity index: robust to the breath-hold-level variations and correlated with clinical parameters. |
| Q42741129 | Adaptive quantification and longitudinal analysis of pulmonary emphysema with a hidden Markov measure field model |
| Q34628584 | Advanced imaging in COPD: insights into pulmonary pathophysiology |
| Q38963069 | Advances in Imaging and Automated Quantification of Pulmonary Diseases in Non-neoplastic Diseases. |
| Q47946520 | Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies |
| Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
| Q40333027 | Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study |
| Q90353444 | Assessing pulmonary hypertension in COPD. Is there a role for computed tomography? |
| Q37620204 | Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. |
| Q37270967 | Biomarkers in airway diseases |
| Q49667007 | Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop. |
| Q26996356 | Biomarkers of progression of chronic obstructive pulmonary disease (COPD) |
| Q38546748 | Biomarkers, the control panel and personalized COPD medicine. |
| Q37428210 | Body height as risk factor for emphysema in COPD. |
| Q87428160 | COPD: no gene left unturned |
| Q41400890 | CT Scanning in COPD - Is it Time to Move On? |
| Q36185850 | CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society |
| Q52983470 | CT-diagnosed emphysema and lung cancer mortality: novel association or old news? |
| Q40880055 | Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. |
| Q92589961 | Chemokines in COPD: From Implication to Therapeutic Use |
| Q40028685 | Chronic Hypoxia Accentuates Dysanaptic Lung Growth |
| Q89219136 | Chronic obstructive pulmonary disease |
| Q38541559 | Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung |
| Q36516546 | Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD) |
| Q53100833 | Computed tomography biomarkers of pulmonary emphysema. |
| Q38604667 | Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. |
| Q92029835 | DSP variants may be associated with longitudinal change in quantitative emphysema |
| Q39146133 | Decrease in Small Pulmonary Vessels on Chest Computed Tomography in Light Smokers Without COPD: An Early Change, but Correlated with Smoking Index |
| Q26764897 | Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁ |
| Q38832928 | Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency |
| Q46339781 | Disease Severity Dependence of the Longitudinal Association Between CT Lung Density and Lung Function in Smokers. |
| Q47777005 | Disease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography. |
| Q64930474 | Disease-Specific Comorbidity Clusters in COPD and Accelerated Aging. |
| Q26998557 | Early chronic obstructive pulmonary disease: definition, assessment, and prevention |
| Q90259092 | Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study |
| Q42323707 | Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy |
| Q40051782 | Effect of smoking cessation on quantitative computed tomography in smokers at risk in a lung cancer screening population |
| Q36208201 | Emphysema Distribution and Diffusion Capacity Predict Emphysema Progression in Human Immunodeficiency Virus Infection |
| Q89513464 | Five-year Progression of Emphysema and Air Trapping at CT in Smokers with and Those without Chronic Obstructive Pulmonary Disease: Results from the COPDGene Study |
| Q58694875 | Fractal analysis of low attenuation clusters on computed tomography in chronic obstructive pulmonary disease |
| Q41493817 | Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis |
| Q53028581 | Imaging biomarkers in the clinic. |
| Q53822322 | Imbalance between endothelial damage and repair capacity in chronic obstructive pulmonary disease. |
| Q26775074 | Increasing awareness of sex differences in airway diseases |
| Q28388015 | Intercellular adhesion molecule 1 and progression of percent emphysema: the MESA Lung Study |
| Q33743024 | Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence |
| Q38604674 | Longitudinal Computed Tomography and Magnetic Resonance Imaging of COPD: Thoracic Imaging Network of Canada (TINCan) Study Objectives |
| Q90528348 | Longitudinal airway remodeling in active and past smokers in a lung cancer screening population |
| Q53083138 | Longitudinal quantitative low-dose CT in COPD: ready for use? |
| Q39112080 | Lung Mass in Smokers |
| Q48273754 | Lung Parenchymal Assessment in Primary and Secondary Pneumothorax. |
| Q47163543 | Lung densitometry: why, how and when |
| Q92843566 | Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage |
| Q33840296 | Mathematical modeling of GATA-switching for regulating the differentiation of hematopoietic stem cell. |
| Q96306279 | Measures of lung function and their relationship with advanced glycation end-products |
| Q93126824 | Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article |
| Q33796180 | Multiple biomarkers predict disease severity, progression and mortality in COPD. |
| Q47120721 | Natural history of COPD: gaps and opportunities |
| Q35975285 | Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis |
| Q46165199 | Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease |
| Q47987081 | Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease |
| Q26777927 | Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? |
| Q41434336 | Progress in Imaging COPD, 2004 - 2014. |
| Q37551440 | Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes. |
| Q28067775 | Quantitative computed tomography imaging in chronic obstructive pulmonary disease |
| Q34166577 | Quantitative computed tomography in chronic obstructive pulmonary disease |
| Q57281867 | Quantitative computed tomography phenotypes, spirometric parameters, and episodes of exacerbation in heavy smokers: An analysis from South America |
| Q33766475 | Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease |
| Q36891654 | Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study |
| Q64270436 | Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD |
| Q54757715 | Receptor for advanced glycation end products and soluble receptor for advanced glycation end products: a balancing act in chronic obstructive pulmonary disease? |
| Q62731127 | Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review |
| Q51553940 | Regional Heterogeneity of Chronic Obstructive Pulmonary Disease Phenotypes: Pulmonary (3)He Magnetic Resonance Imaging and Computed Tomography. |
| Q92116005 | Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives |
| Q39622012 | Rosiglitazone attenuates the metalloprotease/anti-metalloprotease imbalance in emphysema induced by cigarette smoke: involvement of extracellular signal-regulated kinase and NFκB signaling |
| Q92460681 | Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study |
| Q93150096 | Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial |
| Q51159286 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. |
| Q64090020 | Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD |
| Q33613288 | Soluble receptor for advanced glycation end-products and progression of airway disease |
| Q26823290 | Sources of variation in quantitative computed tomography of the lung |
| Q55269439 | Surfactant Protein D in Respiratory and Non-Respiratory Diseases. |
| Q57955627 | Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage |
| Q34636461 | Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease |
| Q51020329 | Surfactant protein-D deficiency suppresses systemic inflammation and reduces atherosclerosis in ApoE knockout mice. |
| Q43779676 | Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease |
| Q38941136 | Texture-based Quantification of Centrilobular Emphysema and Centrilobular Nodularity in Longitudinal CT Scans of Current and Former Smokers |
| Q47962475 | The Challenges of Precision Medicine in COPD. |
| Q47659859 | The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency |
| Q36555278 | The Swedish CArdioPulmonary BioImage Study: objectives and design |
| Q37362027 | The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis |
| Q38208185 | The path to personalised medicine in COPD. |
| Q42634551 | The value of blood cytokines and chemokines in assessing COPD. |
| Q90528497 | Time-series hyperpolarized xenon-129 MRI of lobar lung ventilation of COPD in comparison to V/Q-SPECT/CT and CT |
| Q38215807 | Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. |
| Q57815909 | Validation of lung density indices by cardiac CT for quantification of lung emphysema |
| Q34490119 | Variation of densitometry on computed tomography in COPD--influence of different software tools |
Search more.